Proactive Investors - Run By Investors For Investors

US$1mln grant testament to Redx Pharma’s ‘innovation and research prowess’

“That [Redx] has attracted such an award is testament to its innovation and research prowess in the development of novel antibiotics”
medical research lab
Shares in the drug developer gained almost 20% this week

Shares in Redx Pharma Plc (LON:REDX) boomed this week after the drug developer was awarded a US$1mln grant from a US-UK partnership set up to accelerate the development of new antibiotics.

The money from CARB-X will allow Redx to move its Gram-negative antibacterial programme into the next stage of development with a prospective partner.

City broker Cantor Fitzgerald said the grant reflects the importance of the antibiotic research being carried out by Redx.

“That this programme has attracted such an award is testament to its innovation and research prowess in the development of novel antibiotics to treat the threat from emerging resistance to Gram-negative bacteria,” wrote analyst Brian White in a note to clients on Friday.

Drug resistant Gram-negative are becoming an increasingly problematic in healthcare settings, White added.

The analyst also points out that to win the award, Redx had to go through a “highly competitive process”. Of the 168 initial applicants, only eleven firms, including Redx, received any form of funding.

“This award is important and timely given that Redx has refocused its business in order to capitalise on its close to clinic candidates in its focus areas of cancer and immunology,” said White.

“Consequently, this external funding allows this important area of research and development to continue.”

The oncology pipeline is still king though, and Redx’s RXC004 first-in-class Porcupine inhibitor programme which targets hard-to-treat cancers is scheduled to enter the clinic later this year.

RXC005 – the best-in-class BTK inhibitor – is set to start clinical trials next year.

White reckons the stock is worth 105p, almost triple its current value.

Shares closed 5% higher at 37.1p on Friday.

View full REDX profile

Redx Pharma Plc Timeline

Related Articles

a child with asthma using an inhaler
September 22 2016
Phase II results for its prospective asthma treatment are due next year, while its LOXL2 collaboration with Pharmaxis is set for a Phase I trial in 2017
March 28 2017
2017 is going to be quite action packed we believe we have positioned the company for when RNA interference transforms from a technology to its promise of a new class of therapeutics - boss Ali Mortazavi.
picture of drug research
February 20 2017
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use